ABSTRACT
INTRODUCTION
The annexin I gene (ANXA I or lipocortin I), located on chromosome 9q11-q21 (1, 2) , is divided into 13 exons encoding a protein of 346 amino acid residues starting from exon 2. The binding protein encoded by annexin I is a pleotrophic, calcium-dependent phospholipid (3) whose ascribed functions include inhibition of phospholipase A2 (4) and mediation of apoptosis (5) . It also serves as a substrate for epidermal growth factor receptor (6) and functions as a stress protein (7) . Structurally, annexin I is a component of the cornified envelope (8) and may play an important role in keratinization. Several studies show overexpression of annexin I protein in epithelial malignancies, including breast cancer (9) . In contrast, our studies of esophageal cancer found a high frequency of allelic loss on chromosome 9q (10, 11) and a decrease in expression of the annexin I protein in comparison to normal esophageal mucosa (12, 13) . Thus, in esophageal squamous cell carcinoma, it seems that a loss of this gene's function may be associated with the development of esophageal squamous cell carcinoma. Thus far, the majority of annexin I studies have focused on protein expression; mutation analysis, including germ-line and somatic, have not been reported in tumors, although one study tested for germline mutations in 41 patients with type 2 diabetes (14) . The objective of the current study was to elucidate potential mechanisms responsible for the reported decrease in annexin I expression in esophageal squamous cell carcinoma by analyzing allelic loss, DNA mutations, and alterations in mRNA and protein expression in these tumors.
MATERIALS AND METHODS
Overall Patient Selection. Patients who presented between 1995 and 1999 to the Shanxi Cancer Hospital in Taiyuan, Shanxi Province, People's Republic of China, and were diagnosed with esophageal squamous cell carcinoma and considered candidates for curative surgical resection, were identified and recruited to participate in this study. All patients had a histologic diagnosis of esophageal squamous cell carcinoma confirmed by pathologists at both the Shanxi Cancer Hospital and the National Cancer Institute; no patients had prior therapy, and Shanxi was the ancestral home for all patients. The Institutional Review Boards of the Shanxi Cancer Hospital and the United States National Cancer Institute approved the study.
Patients for Genomic Testing. Fifty-six esophageal squamous cell carcinoma patients were selected to test for loss of heterozygosity (LOH) at loci flanking annexin I using four microsatellite markers. In addition, single-strand conformation polymorphism (SSCP) plus DNA sequencing were performed to identify variants along the entire coding sequence. The demographic characteristics of these original 56 esophageal squamous cell carcinoma patients were previously described (15) along with TP53, BRCA2, and DICE1 gene mutation results (16 -18) . Eighty additional esophageal squamous cell carcinoma patients and 232 healthy individuals (101 from Beijing and 131 from Yangcheng in Shanxi Province) were specifically analyzed for germ-line variants identified in the initial 56 esophageal squamous cell carcinomas. Details of this set of patients and healthy individuals were also reported previously (18) .
Patients for Expression Analysis. RNA expression using real-time reverse transcription-PCR (RT-PCR) was performed on a separate set of 37 patients with archived frozen tumor.
Patients for Protein Analysis. An annexin I IHC antibody was used to evaluate protein expression in 44 of the original 56 cases in which there was sufficient paraffin block material available.
Biological Specimen Collection and Processing. Ten milliliter of venous blood was taken from each patient before surgery, and genomic DNA was extracted and purified using standard methods. Tumor tissue obtained during surgery was fixed in ethanol or formalin and embedded in paraffin or snapfrozen in liquid nitrogen and stored at Ϫ80°C until used.
Laser Capture Microdissection (LCM) and Extraction of Tumor DNA. Tumor cells were harvested using LCM and DNA was extracted using methods described previously (15, 19) .
Microsatellite Marker, PCR, and LOH Analysis. Four microsatellite markers, D9S166 (233-261 bp), D9S1822 (157-163 bp), D9S1876 (132-156 bp), and D9S175 (200 -261 bp; Human MapPairs; Research Genetics, Huntsville, AL) were used to evaluate the regions flanking the annexin I gene (located between D9S1822 and D9S1876 for LOH. 7 The distances separating the four microsatellite markers evaluated are as follows: 0.5 cM between D9S166 and D9S1822; 1.0 cM between D9S1822 and D9S1976; and 2.0 cM between D9S1876 and D9S175. PCR reactions, LOH gel methods, and interpretations were performed as described previously (15) .
Mutational Testing By SSCP and DNA Sequencing. PCR primers for the promoter region of annexin I gene and all 13 of its exons, including intron/exon boundaries, were designed according to the GenBank nucleotide sequences (accession numbers 12735231 and 27482052 for exon 2 to exon 13 and U25414 for promoter region and exon 1). Six pairs of primers were used to cover the promoter region, excluding the first 49 nucleotides that form several hairpin loops and dimers that are less amenable to PCR amplification (Table 1) . Microdissected tumor DNA was obtained from resection specimens, and genomic DNA was extracted from venous blood. PCR reactions were carried out using a 10-L final volume containing 1. 32 P] dCTP. Typical PCR conditions were as follows: 10 minutes of denaturation at 94°C, followed by 35 1-minute cycles at 94°C, then 51°C to 58°C for 1 minute, and finally 72°C for 1 minute. An elongation step at 72°C for 10 minutes was added to the final cycle for each exon and the promoter region. Labeled PCR products were run on SSCP gels, and the size of each PCR product is shown in Table 1 . SSCP and DNA sequencing analysis were conducted according to previously described methods (16) .
Total RNA Extraction, Quantitative Real-Time RT-PCR, and Relative Standard Curve. Total RNA was extracted from frozen tumor and matched normal tissues using a TRIzol reagent (Life Technologies, Inc., Grand Island, NY) according to the manufacturer's protocol. The quality and quantity of RNA were determined with an RNA 6000 Labchip/ Aligent 2100 Bioanalyzer (Agilent Technologies, Germantown, MD) or by electrophoresis with a 1.2% denaturing agarose gel and spectrophotometer. Extracted RNA was purified using RNeasy Mini kit (Qiagen, Inc., Valencia, CA) and Rnase-Free Dnase Set digestion (Qiagen, Inc.). Reverse transcription of RNA was performed by adding 5 g of total RNA, 1 L of oligo(dT) [12] [13] [14] [15] [16] [17] [18] (500 g/mL), 1 L (200 units) of the Superscript II reverse transcriptase,1 L (2 units) of Escherichia coli Rnase, and 1 L 10 mmol/L deoxynucleoside triphosphate (Invitrogen, Carlsbad, CA). All real-time PCR reactions were performed using an ABI Prism 7000 Sequence Detection System (PerkinElmer Applied Biosystems). Primers and probes for the target (annexin I) and internal control genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed by Perkin-Elmer Applied Biosystems. A singleplex reaction mix was prepared according to the manufacture's protocol of "Assays-on-Demand Gene Expression Products" and included 10 L of TaqMan Universal PCR Master mix, No AmpErase UNG (2ϫ), 1 L of 20ϫ Assays-on-Demand Gene Expression Assay Mix (all gene expression assays have a carboxyfluorescein reporter dye at the 5Ј-end of the TaqMan minor groove binder probe and a nonfluorescent quencher at the 3Ј-end of the probe), and 9 L of cDNA (90 ng) diluted in Rnase-free water, in a total 20 L volume. Every sample was run in triplicate. Thermal cycling conditions consisted of 10 minutes at 95°C denaturation step, 40 7 Internet address: http://www.ncbi.nlm.nih.gov/genemap99, G3map. 15-second cycles at 95°C, and 1 minute at 60°C. Each sample was serially (100, 10, 1, 0.1, and 0.01 ng) diluted 10-fold for real-time PCR analysis in accordance with the standard protocol provided by Perkin-Elmer Applied Biosystems. A relative standard curve quantitation method was performed as described previously (20, 21) . 8 The PCR efficiency (E) was calculated using the formula, E ϭ 10
(1/-slope) Ϫ 1, and ranged from 90 to 100% for our assays (21) . For an example, see Fig. 1 .
Comparative C T Method (2 -⌬⌬ CT ) for Relative Quantitation of Gene Expression. The mean annexin I mRNA expression level for the three real-time quantitative RT-PCR experiments was calculated for each case. Results of the real-time RT-PCR data are presented as C T values, where C T is defined as the threshold PCR cycle number at which an amplified product is first detected. There is an inverse correlation between C T and amount of target: lower target amounts correspond to higher C T values and visa versa. The average C T was calculated for both annexin I and GAPDH and the ⌬C T was determined as the mean of the triplicate C T values for annexin I minus the mean of the triplicate C T values for GAPDH. The ⌬⌬C T represents the difference between the paired tissue samples, as calculated by the formula ⌬⌬C T ϭ (⌬C T of tumor Ϫ ⌬C T of normal). The N-fold differential expression of the annexin I gene for a tumor sample compared with its normal epithelial counterpart was expressed as 2 -⌬⌬ CT (20, 22) . 7 Using the 2 -⌬⌬ CT method, the data are presented as the fold change in the target gene (annexin 1) expression in tumor normalized to an internal control gene (GAPDH) and relative to the nontumor control.
In situ Hybridization. In situ hybridization was carried out according to standard protocols by Molecular Histology Labs, Inc. (Montgomery Village, MD). Radioactive sense and antisense probes were synthesized using IMAGE clone 2459615, MGC ID 5095. 9 Hybridization was carried out on formalin-fixed, paraffin-embedded tissue sections after dewaxing, rehydration, blocking, and prehybridization. Parallel sections were hybridized with sense and antisense probes. Visualization was achieved with emulsion autoradiography and staining with H&E.
IHC Analysis. IHC was performed using annexin I antibodies according to the manufacturer's protocols (Transduction Laboratories, Lexington, KY). In brief, 5-m thick deparaffinized tissue sections were pretreated with 3% H 2 O 2 in methanol for 10 minutes followed by 1 hour in 10% normal goat serum to block endogenous peroxidase activity. Each section was incubated overnight at 4°C with a primary anti-annexin I monoclonal antibody (1:200 dilution; Transduction Laboratories), then exposed at room temperature to a biotinylated antimouse monoclonal antibody (1:500 dilution) and, finally, an ABC solution (Vector Laboratories, Burlingame, CA), each for 1 hour. Slides were developed with 0.02% 3Ј,3Ј-diaminobenzidine solution (Sigma), counterstained with hematoxylin, dehydrated in ethanol, and cleared in xylene. The presence of welldifferentiated, poorly differentiated, and carcinoma in situ (CIS) foci in each tumor was determined along with the staining intensity of each component. Well-differentiated foci generally consisted of cells with low nuclear-to-cytoplasmic ratios, approximating that seen in histologically normal appearing cells, and hard or dense appearing cytoplasm consistent with squamous differentiation. Squamous pearls, or mature appearing cells forming concentric rings, were focally identified in association with well-differentiated areas. Poorly differentiated regions were generally composed of cells with high nuclear-tocytoplasmic ratios and less mature appearing cytoplasm. CIS foci consisted of dysplastic epithelial changes involving the entire thickness of the squamous mucosa without extension through the basement membrane.
Immunohistochemical-LCM LOH Analysis. Well-differentiated and poorly differentiated cellular foci were selected from annexin I immunohistochemically stained slides and microdissected by LCM (400 to 1100 shots, 15 to 30-m pulse diameters). Unstained, ethanol-fixed, paraffin-embedded 5-m thick histologic tissue sections were prepared on glass slides, deparaffinized three times with xylene, rinsed with 100, 95, and 70% ethanol, immunostained with antiannexin I monoclonal antibody (1:100 dilution; Transduction Laboratories) using the EnVision polymer technique on a Dako Autostainer. Counterstaining was performed with Mayer's hematoxylin (Biogenex), after rinses with 70, 95, 100% ethanol, xylene, and air drying. The cells obtained were resuspended in 30 to 90 L solution containing 0.01 mol/L Tris-HCl, 1 mmol/L EDTA, 1% Tween 20, and 0.1 mg/mL proteinase K (pH 8.0) and incubated overnight at 55°C. The mixture was then boiled for 8 minutes to inactive the proteinase K at 95°C. Two microliters of this solution were used for each PCR reaction. PCR reactions and data analysis were carried out as described above.
RESULTS

LOH Analysis of Chromosomal Regions Adjacent to
Annexin I
Forty-six of 56 (82%) esophageal squamous cell carcinoma patients lost an allele at one or more of the four microsatellite markers flanking the annexin I gene; 70% of these cases (39 of 56) had LOH at all of their informative loci. Eight patients showed no LOH and 2 patients were homozygous (uninformative) at all four markers. The LOH frequencies were 88% (21 of 24), 83% (30 of 36), 78% (28 of 36), and 76% (29 of 38) for D9S166, D9S1822, D9S1876, and D9S175 in informative cases, respectively ( Table 2) . 
Mutation and Intragenic Allelic Loss in the Annexin I Gene
SSCP analysis and DNA sequencing of the entire coding sequence for annexin I, including 13 exons, exon/intron boundaries, and all but 49 bp of its promoter region, identified band shifts in exon 1 (16 of 56, 29%) and exon 5 (17 of 56, 30%) and a single case with an anomalous band in exon 3. No mutations or polymorphisms were found in the promoter region. Somatic mutation of annexin I was rare in the esophageal squamous cell carcinoma patients despite the high frequencies of LOH for the four flanking polymorphic markers. One case (SHE340) did have a silent germ-line mutation (GCG3 GCA resulting in Ala3 Ala) at codon 35 of exon 3 and a somatic loss of the wild-type allele at the same loci. This case also contained intragenic allelic losses at exons 1 and 5 and LOH at all three informative microsatellite markers.
Genomic DNA sequencing of abnormal SSCP bands identified in 16 cases, including 15 heterozygotes and a single case homozygous for the variant allele (SHE240), showed a single A3 G nucleotide change at NT5 in exon 1 (A78G), consistent with the reported polymorphic variation at this site (NCBI SNP Cluster ID: rs1131072). Seventy-one percent of the cases (40 of 56) were homozygous for the wild-type genotype (AA), 27% (15 of 56) were heterozygous (AG), and one (2%) was homozygous for the variant (GG), resulting in allele frequencies of 0.85 and 0.15 for A and G, respectively. Nine of 14 heterozygous cases (64%; one failed PCR amplification) had allelic loss, including 5 cases that lost a wild-type allele and 4 cases that lost a variant allele (Table 2) .
DNA sequence analysis of exon 5 identified a single polymorphic A3 G nucleotide substitution without an amino acid change (L109L). Seventy percent (39 of 56) of the cases were homozygous for the wild-type (TTA/TTA), 29% (16 of 56) were heterozygous (TTA/TTG), and 1 case (SHE240; 2%) was homozygous for the variant (TTG/TTG), resulting in allele frequencies of 0.84 and 0.16 for the TTA and TTG alleles, respectively. Eleven of 16 informative cases (69%) showed allelic loss in their tumor, including 7 who lost a wild-type allele and 4 who lost a variant allele ( Table 2) . Fifteen of 16 (94%) cases were informative at both A58G and L109L, and 7 of these cases had intragenic allelic loss at both sites (Table 2) .
To additionally refine the allelic frequencies for the polymorphic loci at exon 1 A58G and exon 5 L109L in this high-risk Chinese population, we analyzed an additional 80 esophageal squamous cell carcinoma patients and 232 healthy individuals. The genotype frequencies for the A58G polymorphism for all esophageal squamous cell carcinoma patients tested (n ϭ 136) were 61% homozygous wild-type (AA), 35% heterozygous (AG), and 4% homozygous variants (GG); allele frequencies were 0.79 and 0.21 for the wild-type (A) and variant (G) alleles, respectively. The corresponding genotypic frequencies for the healthy individuals were similar: 65% AA, 31% AG, and 4% GG, with allele frequencies of 0.81 and 0.19 for the A and G alleles, respectively (esophageal squamous cell carcinoma versus healthy individual allele frequencies; Fisher's exact test, P ϭ 0.71). Analysis of the L109L genetic polymorphism showed that esophageal squamous cell carcinoma patients and healthy individuals had identical genotype frequencies [63% homozygous wild-type, 33% heterozygous, 4% homozygous variants; allele frequencies of wild-type (AA), 80%, and variant (GG), 20%]. Table 2 shows the cases with intragenic allelic loss and LOH on four microsatellite markers. Only LOH at D9S1876 was significantly associated with allelic loss at A58G in exon 1 (P ϭ 0.03, two-sided Fisher's exact test), but the case numbers are small (four had allelic loss at both A58G and D9S1876 versus four with loss at neither).
mRNA Expression of Annexin I
Quantitative Real-Time RT-PCR. There was a strong linear relationship between the C T and the log of the RNA concentration of the template (R 2 Ͼ 0.99; Fig. 1 ). PCR efficiency ranged from 92 to 95% for the assays. Eighty-one percent (30 of 37) of the tumors showed a decrease in mRNA expression (median ϭ 0.118, range 0.0006 to 0.6877 as ratio of expression in tumor compared with normal epithelium). In comparison to histologic normal, 19% showed increased expression (median ratio ϭ 13.99, range 1.5121 to 172.4459; Table 3 and Fig. 2) . The means between samples characterized as well and poorly differentiated did not differ because there were admixtures of both cell types in each sample.
In situ Hybridization. Annexin I mRNA levels as assessed by in situ hybridization showed that RNA expression paralleled the cytologic maturation of the squamous epithelium from the basally located less differentiated cells to the more differentiated mucosally located cells (Figs. 3 and 4) . Consequently, poorly differentiated tumor cell foci were negative for annexin I mRNA expression, and the well-differentiated foci were positive. In general, annexin I mRNA expression correlated closely with protein expression as assessed by IHC.
Annexin I Protein Expression
Immunohistochemistry. In general, annexin I protein expression was significantly reduced in the majority of esophageal squamous cell carcinoma. However, protein expression tended to vary with tumor differentiation. Thirty-eight of 44 (86%) esophageal squamous cell carcinoma cases had foci of well-differentiated tumor cells, and nearly all of these (36 of 38 or 95%) showed positive staining for annexin I protein. Fortyone of 44 (93%) contained foci of poorly differentiated tumor cells, and 29% (12 of 41) of these foci showed positive staining for this protein (Fig. 3) . Most of the cases (35 of 44, 80%) contained both well-differentiated and poorly differentiated tumor cells with positive staining largely limited to the welldifferentiated component ( Table 2) . Foci of CIS were present in eight of these cases, and five (62%) reacted positively with antibodies to the annexin I protein. Two dysplastic foci also stained positive.
Immunohistochemical and LCM LOH Analysis. To investigate the relationship between genomic alterations and annexin I protein expression, we microdissected both IHCpositive and -negative regions of five tumors and evaluated LOH at two microsatellite markers on chromosome 9 located centromeric and telomeric to the gene (Table 4) . In all cases, both regions of each tumor showed allelic loss in at least one marker.
DISCUSSION
In previous reports, we described a decrease in annexin I protein expression in esophageal squamous cell carcinoma in comparison to matched normal esophageal mucosa (12, 13) . To elucidate potential mechanisms for this decrease, the current study examined the genomic, transcriptional, and protein alterations of annexin I in esophageal squamous cell carcinoma tumors. LOH of chromosomal regions flanking annexin I was frequent as was intragenic allelic loss at two polymorphic sites.
In addition, we identified an association between allelic loss at the A58G polymorphism and D9S1876, a neighboring microsatellite marker, plus a single silent mutation. However, no significant relationship between genomic alterations on chromosome 9 and annexin I expression was determined.
The results presented here represent the first report of genotype and allele frequencies for two SNPs in annexin I (G58A and L109L) in esophageal squamous cell carcinoma patients and healthy individuals from a high-risk population in northern China. A58G was previously reported in a case-control study of type 2 diabetes in Finland and Sweden, where the frequency of the variant allele (G) was 0.05 in control subjects (14) , much lower than we observed in healthy individuals (0.19), suggesting that the variant allele distribution of this SNP varies by ethnicity. It seemly likely that the reason we saw no significant relationship between genomic alterations on chromosome 9 and annexin I is because heterozygosity of these two SNPs was relatively low (29%), and homozygous deletions cannot be detected by SSCP, the technique used here. However, 81% of the 16 patients who were heterozygous showed intragenic allelic loss at one or both SNPs, including 10 (77%) who also had LOH at one or more of the microsatellite markers flanking annexin I that were tested. Thus, these results indicate that there is some level of genetic instability in esophageal squamous cell carcinoma patients, and additional study of these two SNPs in larger numbers of subjects is warranted to determine whether they are associated with increased susceptibility to esophageal squamous cell carcinoma in this high-risk population.
Quantitative RT-PCR identified decreased expression of annexin I mRNA in most esophageal squamous cell carcinoma. Thus far, only one other study of esophageal squamous cell carcinoma has reported decreased expression of annexin I RNA (in 17 of 24 esophageal squamous cell carcinomas), but expression levels were not quantitated in that study (23) . To our knowledge, the current study represents the first published data on annexin I mRNA using a quantitative real-time RT-PCR method in esophageal squamous cell carcinoma. We also noted that 19% of patients had increased expression of RNA of this gene. Possible explanations for this include: (a) our use of LCM DNA for mutation analysis without separation of RNA from well-differentiated and poorly differentiated foci; (b) direct extraction of RNA from frozen tumor tissue without LCM separation of well-differentiated from poorly differentiated and with potential admixture of normal tissue with tumor; and (c) general heterogeneity among patients.
Annexin I protein expression in esophageal squamous cell carcinoma showed a decrease in foci of poorly differentiated tumor cells but positive expression in the limited number of dysplastic and CIS lesions studied here. Future testing of protein expression with larger numbers of samples, as from biopsies with dysplasia or CIS, should help clarify these unexpected findings and aid in further understanding of annexin I protein expression in the development of esophageal squamous cell carcinoma.
The clinical relevance of the findings presented here stem from the advancement of our understanding of the mechanism of action of annexin I. These data strongly suggest that the loss of annexin I expression in squamous esophageal carcinogenesis is transcriptionally controlled and is unrelated to genomic mutations or epigenetic events. These data also provide confirmatory evidence regarding the high frequency of loss of expression and establish annexin I as a solid candidate for additional testing as an early detection marker for esophageal squamous cell carcinoma.
There are several potential limitations in our approaches that merit comment. First, we did not have sufficient materials available to perform our DNA, RNA, and protein analyses on the same patients. Although there was substantial overlap in the patients evaluated for DNA and protein, we had no frozen tissue on the core 56 patients studied here, so we relied on a new set of patients for our mRNA analyses. Although the patients came from the same region of China and presented to the same cancer hospital, we cannot account for the degree of discordance that was introduced. Second, we may have underestimated the frequency of annexin I gene mutations because SSCP does not detect homozygous deletions. Third, we used LCM DNA for mutation analysis, but we did not separate DNA from well-differentiated and poorly differentiated areas and that may have masked differences between well-and poorly differentiated cellular foci for both DNA and RNA analyses.
Fourth, we did not use laboratory techniques to identify changes in transcriptional or posttranslational modifications that may affect relevant downstream events and thus have no information on potential influences of these phenomena. Finally, the relatively small number of heterozygotes limited our ability to fully evaluate intragenic allelic loss.
One analysis we chose not to conduct, gene methylation, warrants mention given its frequent association with decreased gene expression in cancer. Gene methylation was deemed to be an unlikely silencing mechanism for annexin I because there are no CpG islands in either the promoter or coding region of this gene, the potential sites where gene methylation occurs. However, one recent study found that treating B-cell non-Hodgkin's lymphoma cell lines with 5-aza-2-deoxycytidine did result in reexpression of annexin I protein (24) . It remains unclear whether this result reflects demethylation of genes upstream from annexin I or changes in annexin I itself.
In summary, intragenic allelic loss involving the annexin I gene occurs frequently, whereas somatic mutations are rare. However, loss of annexin I protein expression was confirmed, quantitated through mRNA expression analyses, and shown to be related to tumor cell differentiation. The most likely explanation for the loss of protein expression is an alteration in transcription. Thus, changes in annexin I mRNA and protein expression may be involved in the development of esophageal squamous cell carcinoma. The high prevalence of protein loss indicates that annexin I is a strong candidate for inclusion in a panel of early detection markers for esophageal squamous cell carcinoma. 
Abbreviations: B, blood DNA; N, LCM DNA from adjacent normal tissue, annexin I (ϩ/Ϫ) based on ISH result; R, retention; H, homozygous; L, loss of heterozygosity. 
